Alnylam Pharmaceuticals
ALNY
#582
Rank
NZ$60.22 B
Marketcap
$465.30
Share price
4.33%
Change (1 day)
83.90%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.41 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.24 Billion. , an increase over its 2023 earnings that were of -NZ$0.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -NZ$0.42 Billion-24.59%
2023 -NZ$0.55 Billion-67.84%
2022 -NZ$1.7 Billion36.93%
2021 -NZ$1.24 Billion-8.04%
2020 -NZ$1.35 Billion-15.66%
2019 -NZ$1.6 Billion12.23%
2018 -NZ$1.43 Billion62.91%
2017 -NZ$0.88 Billion17.78%
2016 -NZ$0.75 Billion43.44%
2015 -NZ$0.52 Billion60.69%
2014 -NZ$0.33 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$95.6 Million27.48%
2010 -NZ$74.99 Million-10.92%
2009 -NZ$84.18 Million95.77%
2008 -NZ$43 Million
2006 -NZ$68.89 Million-9.13%
2005 -NZ$75.81 Million34.74%
2004 -NZ$56.27 Million36.79%
2003 -NZ$41.13 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$1.05 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.33 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.45 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$18.08 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$80.57 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$23.78 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$13.84 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-NZ$0.5 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel